Optimizing CDK4/6 Inhibition in HR+ Breast Cancer

preview_player
Показать описание
Stephen Johnston, MA, PhD, FRCP, and Joyce A. O’Shaughnessy, MD, discuss how proper sequencing and selection of an endocrine partner can optimize the treatment of hormone receptor–positive breast cancer.
  1. OncLive
  2. cancer
  3. oncology
Рекомендации по теме
Optimizing CDK4/6 Inhibition 0:03:04

Optimizing CDK4/6 Inhibition in HR+ Breast Cancer

Unmet needs and 0:02:06

Unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancer

HR+ mBC: Factors 0:06:18

HR+ mBC: Factors in Selecting CDK4/6 Inhibitions

Dr Ma on 0:02:07

Dr Ma on Questions Regarding Treatment Sequencing in CDK4/6 Inhibitor–Resistant Breast Cancer

Optimizing adjuvant therapy: 0:01:19

Optimizing adjuvant therapy: chemotherapy necessity in HR-positive breast cancer

Unmet needs in 0:01:11

Unmet needs in the use of CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer

Dr. Tolaney on 0:01:00

Dr. Tolaney on Remaining Questions With CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Combining JAK, PIM 0:03:41

Combining JAK, PIM kinase and CDK4/6 inhibition in MPNs

Raising the Bar 1:09:24

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors

Navigating Between Endocrine 0:32:14

Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2...

The Role of 0:06:02

The Role of RWE in Addressing Underrepresented Patients in CDK4/6 Inhibitor RCTs

Prognostic value of 0:03:07

Prognostic value of intrinsic subtypes in HR+/HER2- breast cancer after CDK4/6 inhibitors

Adjuvant CDK4 and 0:58:22

Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast Cancer

HR+, HER2 , 0:55:49

HR+, HER2 , High Risk EBC A Practical Roadmap for CDK4 6 Inhibition in the Adjuvant Setting

Dr. Goetz on 0:02:17

Dr. Goetz on Treatment Beyond Progression on CDK4/6 Inhibitors in HR+ Breast Cancer

Real World Evidence 0:05:41

Real World Evidence To Expand Knowledge of CDK4/6 Inhibitor-Related Adverse Effects

Integrating Adjuvant CDK4/6 0:17:47

Integrating Adjuvant CDK4/6 Therapy for HR+/Her2- EBC | Dr. Naresh Somani | Oncology 2024

ESMO Daily Reporter 0:21:47

ESMO Daily Reporter Talk: The role of CDK4/6 inhibitors in the early stage of #breastcancer.

Part 2 - 1:06:57

Part 2 - Session 1 - CDK 4/6 Inhibitors in breast cancer: will they have a Large role in future?

RWE Supporting CDK4/6 0:04:48

RWE Supporting CDK4/6 Inhibitor Use in HR+ Metastatic Breast Cancer

Adjuvant Abemaciclib/Ribociclib #monarchE/NATALEE 0:29:10

Adjuvant Abemaciclib/Ribociclib #monarchE/NATALEE #Best Treatment for Breast cancer #CDK 4/6 -Cure

CDK4/6 Inhibitor Maintained 0:04:28

CDK4/6 Inhibitor Maintained OS Benefit in Advanced Breast Cancer - Medpage Today

CDK4/6 Inhibitors & 0:04:17

CDK4/6 Inhibitors & Endocrine Therapy in Breast Cancer

CDK4/6 Inhibitors Breast 0:08:47

CDK4/6 Inhibitors Breast Cancer Nemeses is the EBC Party Over for Real-World Dance-Off?